Compare PCT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | GERN |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | United States |
| Employees | 174 | 258 |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 821.1M |
| IPO Year | N/A | N/A |
| Metric | PCT | GERN |
|---|---|---|
| Price | $11.27 | $1.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $13.00 | $2.17 |
| AVG Volume (30 Days) | 4.7M | ★ 14.2M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $380.44 | $26.91 |
| Revenue Next Year | $203.33 | $43.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.93 | $1.04 |
| 52 Week High | $17.37 | $2.01 |
| Indicator | PCT | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 67.12 | 32.94 |
| Support Level | $7.87 | $1.24 |
| Resistance Level | $15.13 | $1.29 |
| Average True Range (ATR) | 0.85 | 0.09 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 66.58 | 10.42 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.